Antibody-Drug Conjugate I-DXd Shows Clinically Meaningful Response in Patients with Extensive-Stage Small Cell Lung ...
The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study. SAN DIEGO, …